Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JVS 100

Next Previous
Search
Drug Profile

JVS 100

Alternative Names: ACRX-100; JVS-100; SRX-100

Latest Information Update: 28 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cleveland Clinic
  • Developer Juventas Therapeutics; SironRX Therapeutics
  • Class Gene therapies; Heart failure therapies
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; CXCR4 receptor agonists; Gene transference; Leukocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic limb-threatening ischemia; Heart failure; Peripheral arterial disorders
  • No development reported Angina pectoris; Faecal incontinence; Myocardial infarction; Scars

Most Recent Events

  • 28 Dec 2022 No recent reports of development identified for preclinical development in Faecal-Incontinence in USA (IM, Injection)
  • 01 Aug 2020 Juventas completes a phase II STOP-PAD trial for Peripheral arterial disorders in USA (NCT02544204)
  • 22 Nov 2018 JVS 100 licensed to Astellas Pharma worldwide, except China, for the treatment of faecal incontinence

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top